Eldricare

eldricare.com

EldriCare is a population health management company that combines innovative technology with outstanding care management services. We make a difference in people’s lives by effectively engaging them to improve their health. Our expert care teams leverage predictive analytics, the most advanced care management platform in the world, and patient engagement technology to guide, impact, and personalize the care experience.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

GENSCRIPT LAUNCHES GMP SINGLE-STRAND AND DOUBLE-STRAND DNA SERVICE FOR SUPPORTING GENE AND CELL THERAPY DEVELOPMENT

GenScript | May 18, 2022

news image

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services. These services will enable next-generation gene and cell therapy R&D programs to advance to IND filing and clinical trials faster and more efficiently. Today's announcement, made at the American Society of Gene & Ce...

Read More

SEATTLE GENETICS AND ASTELLAS' PADCEV WINS BREAKTHROUGH THERAPY DESIGNATION IN BLADDER CANCER

BioSpace | February 20, 2020

news image

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

Read More

Medical

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

news image

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

news image

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More
news image

Medical

GENSCRIPT LAUNCHES GMP SINGLE-STRAND AND DOUBLE-STRAND DNA SERVICE FOR SUPPORTING GENE AND CELL THERAPY DEVELOPMENT

GenScript | May 18, 2022

GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services. These services will enable next-generation gene and cell therapy R&D programs to advance to IND filing and clinical trials faster and more efficiently. Today's announcement, made at the American Society of Gene & Ce...

Read More
news image

SEATTLE GENETICS AND ASTELLAS' PADCEV WINS BREAKTHROUGH THERAPY DESIGNATION IN BLADDER CANCER

BioSpace | February 20, 2020

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

Read More
news image

Medical

DXTERITY DIAGNOSTICS ANNOUNCES THE LAUNCH OF IFN-1 TEST FOR LUPUS

DxTerity | June 13, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus. DxTerity's test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an incr...

Read More
news image

Cell and Gene Therapy

MISSION BIO DEVELOPS SINGLE-CELL SOLUTION TO ADDRESS CHALLENGES IN GENOME EDITING

PR Newswire | May 12, 2023

Mission Bio, the single-cell DNA and multi-omics company, announced today the Tapestri® Genome Editing Solution, an end-to-end product for genome editing analysis. The product will be previewed next week at the American Society of Gene and Cell Therapy Conference (ASGCT) 26th Annual Meeting. By enabling robust single-cell insights impacting both efficacy and safety, the solution will be a powerful analytical tool for developing the next generation of gene-edited therapies. T...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us